Mobile RPP Utilization Increasing, New Centers Added; Strong Commitment from Distribution Partne

Europe's RPP Program: On Track to Group Profitability The USA: EDAP's New and Exciting Opportunity

EDAP Leverages Expertise in Distributing Innovative Urinary Systems

Clear Global Leader in Prostate Cancer HIFU Continues Market Acceleration Strengthening Its Position by Adding New RPP Sites

Ablatherm-HIFU Tours to Accelerate HIFU Adoption for Prostate Cancer, Add New Users and Sites EDAP Marketing Programs Driving Patient Inquiries, Moving Doctors to Action

EDAP TMS S.A. to Release 2006 Year End Financial Results Lyon, France, March 5, 2007 - EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and distribution of a wide

EDAP TMS S.A. to Present at the Roth Capital 2007 Orange County Conference Lyon, France, February 16, 2006 - EDAP TMS S.A. (Nasdaq: EDAP) , the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production, and

Italian Study Shows Up to 90% Efficacy at 12 Months in Stage T2b and T3 High Risk Patients

EDAP TMS S.A. Announces Exclusive Distribution of New Muscle Trainer Device in Japan Lyon, France, January 30, 2007 - EDAP TMS S.A. (Nasdaq: EDAP ), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development,

EDAP Leveraging Positions in Europe for HIFU; Finalizing US Market Strategy